Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

1.

[State of the art treatment of progressive or refractory multiple myeloma].

Schmidt-Wolf IG, Straka C, Scheid C, Einsele H, Goldschmidt H, Engelhardt M.

Dtsch Med Wochenschr. 2014 Oct;139(41):2091-5. doi: 10.1055/s-0034-1387268. Epub 2014 Sep 30. Review. German.

PMID:
25268212
2.

Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.

Stohl W.

Expert Opin Ther Targets. 2014 Apr;18(4):473-89. doi: 10.1517/14728222.2014.888415. Epub 2014 Feb 13. Review.

PMID:
24521424
3.

The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.

Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F.

Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15. doi: 10.1016/j.cytogfr.2013.04.003. Epub 2013 May 15. Review.

PMID:
23684423
4.

B-cell targeted therapeutics in clinical development.

Blüml S, McKeever K, Ettinger R, Smolen J, Herbst R.

Arthritis Res Ther. 2013;15 Suppl 1:S4. doi: 10.1186/ar3906. Epub 2013 Apr 4. Review.

5.

Treating multiple sclerosis with monoclonal antibodies: a 2013 update.

Deiß A, Brecht I, Haarmann A, Buttmann M.

Expert Rev Neurother. 2013 Mar;13(3):313-35. doi: 10.1586/ern.13.17. Review.

PMID:
23448220
6.
7.

Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

Gensicke H, Leppert D, Yaldizli Ö, Lindberg RL, Mehling M, Kappos L, Kuhle J.

CNS Drugs. 2012 Jan 1;26(1):11-37. doi: 10.2165/11596920-000000000-00000. Review.

PMID:
22171583
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk